热门资讯> 正文
AbCellera与Vertex Pharma达成药物发现协议
2026-07-29 22:24
- AbCellera (ABCL) on Wednesday announced a collaboration with Vertex Pharmaceuticals (VRTX) to discover and conduct early research into certain T-cell engagers targeting conditions such as autoimmune diseases.
- As part of the deal, the Canadian firm is expected to leverage its T-cell engager platform to discover multispecific TCEs that Vertex (VRTX) will have the right to develop further and commercialize.
- In exchange, the company will receive $28M in total upfront payments as well as milestone payments, subject to its ability to hit preclinical, development, regulatory, and commercial targets.
- Vertex (VRTX) is also expected to fund all research and development activities and provide AbCellera (ABCL) with tiered royalties on net sales of products resulting from the partnership.
- Additionally, AbCellera (ABCL) can perform cell line development, process development, and clinical manufacturing through Phase 1 development if both companies agree to such an arrangement.
More on AbCellera Biologics, Vertex Pharmaceuticals
- Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know
- Vertex Pharmaceuticals Incorporated (VRTX) M&A Call Transcript
- Vertex Pharmaceuticals Incorporated (VRTX) Crinetics Pharmaceuticals, Inc. - M&A Call - Slideshow
- Key deals this week: MGM, PERF, VRTX, and more
- Meta logs highest weekly gains as tech lifts Nasdaq
推荐文章
美股前瞻 | 今晚凌晨两点！贝森特公布对伊”史诗级金融攻势“；拼多多绩后涨逾4%！此前一度跌近5%；存储、光通信盘前齐跌
一图看懂 | 拼多多Q2营收增约8%！经调整净利略超市场预期，研发投入同比大增40%
一图看懂 | 小鹏集团Q2毛利率20.7%超预期！旗下机器人子公司完成9亿美元融资，将正式布局人形机器人赛道
美股盘前 | 存储概念普跌，闪迪跌超4%；阿里巴巴跌超3.5%，宣布800亿港元港股配售；
美扩大国债回购难抑收益率 比特币黄金应声大涨
阿里巴巴融资800亿股价大跌，市场热议港股“二次探底”
阿里重挫10%拖累恒科！港股史上最大配售落地，800亿港元全押AI遭“大空头”开炮，主权基金却逆势抢筹？
沃什若未提供明确指引 美国长债恐遭进一步抛售
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
